Shanghai Net Interest Income vs Operating Income Analysis

601607 Stock

20.15 0.32 1.61%

Shanghai Pharmaceuticals financial indicator trend analysis is much more than just breaking down Shanghai Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Shanghai Pharmaceuticals is a good investment. Please check the relationship between Shanghai Pharmaceuticals Net Interest Income and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shanghai Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Interest Income vs Operating Income

Net Interest Income vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Shanghai Pharmaceuticals Net Interest Income account and Operating Income. At this time, the significance of the direction appears to have pay attention.

The correlation between Shanghai Pharmaceuticals' Net Interest Income and Operating Income is -0.88. Overlapping area represents the amount of variation of Net Interest Income that can explain the historical movement of Operating Income in the same time period over historical financial statements of Shanghai Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Shanghai Pharmaceuticals' Net Interest Income and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Interest Income of Shanghai Pharmaceuticals Holding are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Net Interest Income i.e., Shanghai Pharmaceuticals' Net Interest Income and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.88

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Operating Income

Operating Income is the amount of profit realized from Shanghai Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Shanghai Pharmaceuticals Holding is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Shanghai Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Shanghai Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shanghai Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of January 31, 2025, Selling General Administrative is expected to decline to about 6.7 B. In addition to that, Tax Provision is expected to decline to about 1.6 B

	2022	2023	2024	2025 (projected)
Operating Income	8.8B	9.6B	11.0B	11.5B
Total Revenue	232.0B	260.3B	299.3B	314.3B

Operating Income Total Revenue

Shanghai Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Short Term Investments	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Other Liab	Good Will	Net Tangible Assets	Other Stockholder Equity	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Total Current Assets	Short Term Debt
Total Assets		0.79	1.0	0.99	0.99	1.0	0.98	0.74	0.74	1.0	0.91	1.0	0.25	1.0	0.76	0.85	0.98	0.97	0.83	0.86	-0.46	0.57	0.88	0.9	0.9	0.83
Other Current Liab	0.79		0.79	0.72	0.83	0.78	0.74	0.81	0.74	0.81	0.87	0.77	0.74	0.81	0.62	0.6	0.89	0.85	0.9	0.7	-0.72	0.92	0.84	0.78	0.68	0.89
Total Current Liabilities	1.0	0.79		0.98	0.99	0.99	0.97	0.73	0.72	1.0	0.91	0.99	0.25	1.0	0.74	0.83	0.98	0.97	0.82	0.87	-0.45	0.58	0.89	0.91	0.9	0.83
Total Stockholder Equity	0.99	0.72	0.98		0.97	0.99	0.99	0.69	0.67	0.98	0.84	0.99	0.17	0.98	0.8	0.91	0.95	0.94	0.78	0.84	-0.36	0.46	0.83	0.86	0.87	0.76
Retained Earnings	0.99	0.83	0.99	0.97		0.99	0.96	0.77	0.75	0.99	0.9	0.99	0.34	0.99	0.74	0.82	0.99	0.99	0.86	0.87	-0.48	0.62	0.9	0.91	0.89	0.86
Accounts Payable	1.0	0.78	0.99	0.99	0.99		0.97	0.76	0.74	1.0	0.88	1.0	0.28	0.99	0.75	0.87	0.97	0.96	0.83	0.84	-0.45	0.55	0.86	0.89	0.88	0.81
Cash	0.98	0.74	0.97	0.99	0.96	0.97		0.66	0.65	0.96	0.86	0.97	0.17	0.97	0.83	0.91	0.94	0.94	0.77	0.83	-0.38	0.49	0.82	0.85	0.87	0.75
Other Assets	0.74	0.81	0.73	0.69	0.77	0.76	0.66		0.84	0.78	0.77	0.76	0.62	0.76	0.41	0.6	0.81	0.75	0.81	0.57	-0.78	0.72	0.8	0.76	0.62	0.82
Long Term Debt	0.74	0.74	0.72	0.67	0.75	0.74	0.65	0.84		0.76	0.83	0.76	0.43	0.76	0.43	0.52	0.76	0.72	0.8	0.58	-0.8	0.72	0.74	0.79	0.67	0.82
Net Receivables	1.0	0.81	1.0	0.98	0.99	1.0	0.96	0.78	0.76		0.92	0.99	0.3	1.0	0.73	0.83	0.98	0.97	0.85	0.86	-0.5	0.61	0.9	0.91	0.89	0.85
Short Term Investments	0.91	0.87	0.91	0.84	0.9	0.88	0.86	0.77	0.83	0.92		0.89	0.38	0.93	0.66	0.64	0.93	0.9	0.87	0.81	-0.71	0.78	0.88	0.89	0.86	0.89
Inventory	1.0	0.77	0.99	0.99	0.99	1.0	0.97	0.76	0.76	0.99	0.89		0.26	0.99	0.75	0.87	0.97	0.95	0.83	0.83	-0.47	0.55	0.86	0.9	0.88	0.82
Other Current Assets	0.25	0.74	0.25	0.17	0.34	0.28	0.17	0.62	0.43	0.3	0.38	0.26		0.28	0.1	0.16	0.42	0.37	0.6	0.18	-0.62	0.79	0.43	0.31	0.14	0.55
Total Liab	1.0	0.81	1.0	0.98	0.99	0.99	0.97	0.76	0.76	1.0	0.93	0.99	0.28		0.74	0.82	0.98	0.97	0.84	0.87	-0.49	0.61	0.9	0.92	0.9	0.85
Intangible Assets	0.76	0.62	0.74	0.8	0.74	0.75	0.83	0.41	0.43	0.73	0.66	0.75	0.1	0.74		0.84	0.73	0.72	0.6	0.67	-0.21	0.37	0.57	0.58	0.66	0.5
Common Stock	0.85	0.6	0.83	0.91	0.82	0.87	0.91	0.6	0.52	0.83	0.64	0.87	0.16	0.82	0.84		0.8	0.78	0.66	0.63	-0.25	0.3	0.62	0.66	0.67	0.55
Property Plant Equipment	0.98	0.89	0.98	0.95	0.99	0.97	0.94	0.81	0.76	0.98	0.93	0.97	0.42	0.98	0.73	0.8		0.99	0.88	0.87	-0.55	0.71	0.92	0.91	0.87	0.9
Other Liab	0.97	0.85	0.97	0.94	0.99	0.96	0.94	0.75	0.72	0.97	0.9	0.95	0.37	0.97	0.72	0.78	0.99		0.85	0.88	-0.47	0.66	0.92	0.91	0.88	0.88
Good Will	0.83	0.9	0.82	0.78	0.86	0.83	0.77	0.81	0.8	0.85	0.87	0.83	0.6	0.84	0.6	0.66	0.88	0.85		0.79	-0.72	0.74	0.91	0.91	0.84	0.96
Net Tangible Assets	0.86	0.7	0.87	0.84	0.87	0.84	0.83	0.57	0.58	0.86	0.81	0.83	0.18	0.87	0.67	0.63	0.87	0.88	0.79		-0.3	0.48	0.91	0.9	0.96	0.82
Other Stockholder Equity	-0.46	-0.72	-0.45	-0.36	-0.48	-0.45	-0.38	-0.78	-0.8	-0.5	-0.71	-0.47	-0.62	-0.49	-0.21	-0.25	-0.55	-0.47	-0.72	-0.3		-0.8	-0.58	-0.58	-0.42	-0.72
Deferred Long Term Liab	0.57	0.92	0.58	0.46	0.62	0.55	0.49	0.72	0.72	0.61	0.78	0.55	0.79	0.61	0.37	0.3	0.71	0.66	0.74	0.48	-0.8		0.68	0.59	0.46	0.77
Long Term Investments	0.88	0.84	0.89	0.83	0.9	0.86	0.82	0.8	0.74	0.9	0.88	0.86	0.43	0.9	0.57	0.62	0.92	0.92	0.91	0.91	-0.58	0.68		0.96	0.91	0.96
Short Long Term Debt	0.9	0.78	0.91	0.86	0.91	0.89	0.85	0.76	0.79	0.91	0.89	0.9	0.31	0.92	0.58	0.66	0.91	0.91	0.91	0.9	-0.58	0.59	0.96		0.96	0.95
Total Current Assets	0.9	0.68	0.9	0.87	0.89	0.88	0.87	0.62	0.67	0.89	0.86	0.88	0.14	0.9	0.66	0.67	0.87	0.88	0.84	0.96	-0.42	0.46	0.91	0.96		0.86
Short Term Debt	0.83	0.89	0.83	0.76	0.86	0.81	0.75	0.82	0.82	0.85	0.89	0.82	0.55	0.85	0.5	0.55	0.9	0.88	0.96	0.82	-0.72	0.77	0.96	0.95	0.86

Click cells to compare fundamentals

Shanghai Pharmaceuticals Account Relationship Matchups

Shanghai Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	149.2B	163.4B	198.1B	212.0B	243.8B	256.0B
Other Current Liab	9.5B	9.7B	6.4B	6.3B	7.2B	7.6B
Total Current Liabilities	88.1B	91.8B	110.7B	122.4B	140.7B	147.8B
Total Stockholder Equity	45.4B	49.4B	67.1B	68.5B	78.8B	82.7B
Retained Earnings	26.9B	30.6B	34.6B	33.8B	38.9B	40.8B
Accounts Payable	37.8B	42.0B	51.6B	54.6B	62.8B	66.0B
Cash	22.3B	22.4B	27.4B	30.5B	35.1B	36.9B
Other Assets	2.9B	5.7B	2.8B	3.0B	3.5B	3.7B
Long Term Debt	1.2B	7.2B	6.3B	5.8B	6.7B	7.0B
Net Receivables	52.7B	58.1B	66.8B	72.9B	83.9B	88.1B
Inventory	24.1B	27.1B	34.5B	36.6B	42.1B	44.2B
Other Current Assets	4.3B	4.2B	1.4B	1.4B	1.6B	1.5B
Total Liab	94.4B	104.4B	120.1B	131.6B	151.4B	159.0B
Intangible Assets	5.4B	6.3B	6.6B	6.4B	7.3B	7.7B
Property Plant Equipment	10.6B	13.1B	14.6B	15.8B	18.2B	19.1B
Other Liab	2.1B	2.7B	3.6B	4.0B	4.5B	4.8B
Good Will	11.3B	11.2B	11.3B	11.4B	13.1B	7.3B
Net Tangible Assets	23.6B	26.9B	28.8B	32.1B	36.9B	28.6B
Other Stockholder Equity	(492.6M)	(542.2M)	(265.4M)	(144.4M)	(130.0M)	(136.5M)
Deferred Long Term Liab	606.4M	639.1M	688.3M	342.6M	394.0M	504.8M
Short Long Term Debt	20.1B	22.5B	27.8B	35.6B	40.9B	21.0B
Total Current Assets	107.6B	116.5B	149.5B	162.4B	186.8B	111.5B
Non Current Assets Total	41.6B	46.9B	48.6B	49.5B	57.0B	42.3B
Non Currrent Assets Other	12.6B	856.9M	443.8M	440.7M	506.8M	481.5M
Non Current Liabilities Total	6.3B	12.5B	9.4B	9.3B	10.7B	9.9B
Non Current Liabilities Other	170.4M	566.1M	257.3M	250.1M	287.7M	274.1M
Net Invested Capital	66.7B	79.0B	101.1B	109.9B	126.4B	86.3B
Net Working Capital	19.4B	24.7B	38.8B	40.1B	46.1B	29.9B
Property Plant And Equipment Net	14.2B	15.4B	16.2B	17.9B	20.6B	16.8B
Capital Lease Obligations	1.5B	1.4B	1.3B	1.6B	1.8B	1.5B
Property Plant And Equipment Gross	21.0B	22.9B	16.2B	17.9B	16.1B	15.5B

Currently Active Assets on Macroaxis

F	Ford Motor
GM	General Motors
S	SentinelOne
GOOG	Alphabet Inc Class C
WD	Walker Dunlop

Other Information on Investing in Shanghai Stock

Balance Sheet is a snapshot of the financial position of Shanghai Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Shanghai Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Shanghai Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Shanghai currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Shanghai Net Interest Income vs Operating Income Analysis

Net Interest Income vs Operating Income

Net Interest Income vs Operating Income Correlation Analysis

Correlation Coefficient

Net Interest Income

Operating Income

Shanghai Pharmaceuticals fundamental ratios Correlations

Shanghai Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Shanghai Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Shanghai Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Assets
Net Receivables	+ 1.0	Total Assets
Inventory	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Net Receivables	+ 1.0	Total Current Liabilities

Deferred Long Term Liab	- 0.8	Other Stockholder Equity
Other Stockholder Equity	- 0.8	Long Term Debt
Other Stockholder Equity	- 0.78	Other Assets
Short Term Debt	- 0.72	Other Stockholder Equity
Other Stockholder Equity	- 0.72	Good Will
Other Stockholder Equity	- 0.72	Other Current Liab